|
|
||||||||
Ann Thorac Surg 2006;81:2339-2340
© 2006 The Society of Thoracic Surgeons
The Cleveland Clinic Foundation, Desk F24, 9500 Euclid Cleveland, OH 44195
(Email: gillinom{at}ccf.org).
We thank Drs Dreyfus and Aubert [1] for their comments concerning our article on commissural closure for repair of mitral commissural prolapse [2]. Recently there has been a great interest in the development of new surgical and percutaneous techniques for the management of heart valve disease [3]. Although some of these new procedures are completely novel, many represent modifications of existing techniques. We believe that commissural closure and annuloplasty falls into the latter category. Nevertheless, we agree with Dreyfus and Aubert [1] that new approaches require validation by collection of both early and long-term results.
In the case of commissural closure with annuloplasty, early and mid-term results are encouraging. We and other authors [4] have observed excellent durability. We have measured transvalvular gradients in all patients operated upon at The Cleveland Clinic Foundation, and we have not identified any patient with mitral stenosis; this is not surprising, given the pliability of leaflet tissue in patients with degenerative disease. We will continue to monitor these patients to obtain long-term data assessing repair durability.
We find this technique attractive because of its simplicity. Using other procedures, management of prolapse at a commissure can be challenging. Although authors have described papillary muscle repositioning to treat this sort of pathophysiology [5], most surgeons have limited experience with manipulation of the subvalvular apparatus. As with other mitral repair procedures, commissural closure incorporates an annuloplasty, and this should optimize repair durability.
It is appropriate to scrutinize new approaches to heart valve disease. Many novel procedures, such as percutaneous aortic valve replacement, challenge fundamental surgical concepts (eg, the native valve must be excised before a prosthesis is inserted). At this point in the evolution of the treatment of heart valve disease, it is incumbent upon surgeons to examine new therapies with an open mind and to apply standard outcome measures and analysis before rendering judgment on the success of new approaches.
| References |
|---|
|
|
|---|
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |